Across the world, asthma is a prominent and widespread respiratory disorder that has a substantial clinical and socioeconomic influence. The classification of asthma subtypes should be performed precisely and effectively, with objectives such as personalized treatments, improved rehabilitation outcomes, and preventing tragic exacerbations.
[...] Read more.
Across the world, asthma is a prominent and widespread respiratory disorder that has a substantial clinical and socioeconomic influence. The classification of asthma subtypes should be performed precisely and effectively, with objectives such as personalized treatments, improved rehabilitation outcomes, and preventing tragic exacerbations. Typical screening approaches are primarily based on spirometry measures, immunologic assessments, and individual clinical diagnoses, and they are commonly affected by limitations such as uncertainty, crossover disparities, and restricted generalizability among various groups of patients. This study utilizes machine learning (ML) methodologies as a Data-Driven Approach (DDA)-based framework for asthma classification to overcome the mentioned challenges. Methodically constructed and evaluated classifiers, such as Random Forest and XGBoost, use the
Asthma Disease Dataset from Kaggle, which consists of demographic data, lung function metrics (FEV1, FVC, FEV1/FVC ratio, and PEFR), and immunoglobulin E (IgE) biomarkers. A wide range of metrics such as accuracy, precision, recall, F1-score, receiver operating characteristic area under the curve (ROC-AUC), and average precision (AP) are used exhaustively to assess the performance of the model. The results indicate that though each model exhibits outstanding forecasting abilities, XGBoost has an enhanced classification capability, especially in recall and AP, which minimizes the proportion of false negatives, resulting in a clinically noteworthy result. The significance of the FEV1/FVC ratio, IgE levels, and PEFR as key indicators is recognized by feature interpretability analysis. These results emphasize the ability of ML-powered evaluation in advancing personalized healthcare and revolutionizing the clinical management of asthma.
Full article